Literature DB >> 1483313

Antiphosphatidylethanolamine antibody as the sole antiphospholipid antibody in systemic lupus erythematosus with thrombosis.

M Karmochkine1, P Cacoub, J C Piette, P Godeau, M C Boffa.   

Abstract

A previously healthy 34-year-old woman, was diagnosed as having systemic lupus erythematosus (SLE), with membranous glomerulopathy which improved rapidly. Neither lupus anticoagulant nor anticardiolipin antibodies were detected in her plasma. After three months of total remission, she developed a severe pulmonary thromboembolism for which no specific biological cause was found. Her plasma was analysed for different antiphospholipid antibodies: lupus anticoagulant and anticardiolipin antibodies were again negative. Using an ELISA prepared with either five different anionic phospholipids or zwitterionic phosphatidylethanolamine, solely an anti-phosphatidylethanolamine IgG was discovered in her plasma. In lupus patients, the presence of antiphospholipid antibodies is now well recognized as a high risk factor for repeated thrombosis and/or recurrent abortions. This case suggests that the presence of antiphosphatidylethanolamine antibody should be investigated in cases of unexplained thrombosis in SLE, where the usual clinical and biological investigations have failed to shed light.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1483313

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  6 in total

Review 1.  Clinical Risk Assessment in the Antiphospholipid Syndrome: Current Landscape and Emerging Biomarkers.

Authors:  Shruti Chaturvedi; Keith R McCrae
Journal:  Curr Rheumatol Rep       Date:  2017-07       Impact factor: 4.592

2.  Absence of antiphospholipid antibodies in Behçet's disease.

Authors:  M Karmochkine; M C Boffa; B Wechsler; J C Piette; P Godeau
Journal:  Ann Rheum Dis       Date:  1993-08       Impact factor: 19.103

3.  Early endosome as a pathogenic target for antiphosphatidylethanolamine antibodies.

Authors:  Songwang Hou; Heike Fölsch; Ke Ke; Joan Cook Mills; Rosalind Ramsey-Goldman; Ming Zhao
Journal:  Proc Natl Acad Sci U S A       Date:  2017-12-11       Impact factor: 11.205

4.  The outcome of ELISA for antiphosphatidylethanolamine antibodies is dependent on the composition of phosphatidylethanolamine.

Authors:  Songwang Hou; Paul E Harper; Nathalie Bardin; Ming Zhao
Journal:  J Immunol Methods       Date:  2016-10-23       Impact factor: 2.303

5.  Influence of Phosphatidylethanolamine Concentration and Composition on the Detection of Antiphosphatidylethanolamine Antibodies by ELISA.

Authors:  Ke Ke; Zachariah I Strango; Paul E Harper; Ming Zhao
Journal:  J Clin Lab Anal       Date:  2016-04-07       Impact factor: 2.352

6.  On the role of phosphatidylethanolamine in the inhibition of activated protein C activity by antiphospholipid antibodies.

Authors:  M D Smirnov; D T Triplett; P C Comp; N L Esmon; C T Esmon
Journal:  J Clin Invest       Date:  1995-01       Impact factor: 14.808

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.